Executive Story EMS: AI and Machine Learning in Drug Discovery
Tuesday, 22 September, 2026 / 04:30 PM - 05:00 PM BRT
About the Session
This executive story session presents how EMS, one of Latin America’s largest pharmaceutical companies, is transforming the drug discovery and development cycle by integrating Artificial Intelligence, Machine Learning, and Large Language Models (LLMs) into its R&D processes. The approach accelerates the identification of therapeutic targets, predicts protein structures, enables virtual compound screening, and optimizes clinical trials, reducing development time from 15–20 years to as little as 5–8 years and initial costs by up to 60%. The case highlights the strategic impact of AI in turning data into faster, safer decisions, improving regulatory governance, and increasing the success rate of new drugs. More than a one-off innovation, EMS’s model demonstrates how AI can be applied end-to-end in critical processes, serving as a replicable reference for other R&D-intensive sectors and practically answering the question: where does AI really generate business value?
